Exposure to Proton Pump Inhibitors and the Risk of Incident Asthma in Patients with Coronary Artery Diseases: A Population-Based Cohort Study

Lin, Tsung-Kun; Tsai, Chin‐Feng; Huang, Jing‐Yang; Pan, Lung-Fa; Jong, Gwo‐Ping

doi:10.3390/jpm12050824

Cited by 2 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We included the most updated meta-analyses and recent original studies. Our results are consistent with previous meta-analyses/original studies which showed a positive association between PPI and stroke 13 , lower respiratory infections 14 , falls 15 , CKD 16 , diarrheal diseases 17 , asthma 18 , 19 , pancreatic cancer 20 , Parkinson’s disease 21 , 22 , and depressive disorders 23 , 24 (Supplementary Data 2 ). Similar to the most recent meta-analyses, we also found no evidence of associations between PPI use and risk of Alzheimer’s disease 25 , colon and rectum cancer 26 , prostate cancer 27 , and breast cancer 27 .…”

Section: Discussionsupporting

confidence: 92%

Individualized prevention of proton pump inhibitor related adverse events by risk stratification

Xia,

He,

Smith

et al. 2024

Nat Commun

View full text Add to dashboard Cite

Proton pump inhibitors (PPIs) are commonly used for gastric acid-related disorders, but their safety profile and risk stratification for high-burden diseases need further investigation. Analyzing over 2 million participants from five prospective cohorts from the US, the UK, and China, we found that PPI use correlated with increased risk of 15 leading global diseases, such as ischemic heart disease, diabetes, respiratory infections, and chronic kidney disease. These associations showed dose-response relationships and consistency across different PPI types. PPI-related absolute risks increased with baseline risks, with approximately 82% of cases occurring in those at the upper 40% of the baseline predicted risk, and only 11.5% of cases occurring in individuals at the lower 50% of the baseline risk. While statistical association does not necessarily imply causation, its potential safety concerns suggest that personalized use of PPIs through risk stratification might guide appropriate decision-making for patients, clinicians, and the public.

show abstract

Section: Discussionsupporting

confidence: 92%

Individualized prevention of proton pump inhibitor related adverse events by risk stratification

Xia,

He,

Smith

et al. 2024

Nat Commun

View full text Add to dashboard Cite

show abstract

Proton-pump inhibitors are associated with an increased risk of asthma: A nationwide nested case-control study

Wang,

Li,

Chang

et al. 2023

allergy asthma proc

View full text Add to dashboard Cite

Background: Proton-pump inhibitors (PPI) are among the most widely used drugs worldwide. However, the association between PPI use and the risk of asthma remains unclear. Objective: To investigate the association between PPI use and subsequent asthma risk. Methods: We included participants from the Taiwan National Health Insurance Research Database between 1999 and 2013. Patients who used PPIs and experienced new-onset asthma (n = 20,344) were assigned to the case cohort and matched in a 1:1 ratio with controls who did not subsequently develop asthma. PPI use was defined as > 30 cumulative defined daily doses (cDDD); non-PPI use was defined as ≤ 30 cDDDs. The Charlson Comorbidity Index (CCI) score was used for clinical prognosis and comorbidity adjustment. Multivariate Cox regression models were used for the calculation of adjusted odds ratios (OR). Results: There was a significant and dose-dependent association between PPI use and the risk of developing asthma. The adjusted ORs were 1.24 (95% confidence interval [CI], 1.15‐1.33), 1.39 (95% CI, 1.28‐1.50), and 1.61 (95% CI, 1.43‐1.81) for the male subject with 31‐120 cDDDs, 120‐365 cDDDs, and >365 cDDDs, respectively, compared with PPI nonusers. Men were at higher risk of developing asthma with longer PPI use compared with women. Stratified analyses based on the PPI type showed that exposure to lansoprazole, pantoprazole, omeprazole, and esomeprazole was associated with subsequent asthma risk. Conclusion: Extended use of PPIs was found to be linked to an increased risk of asthma development. This association remained consistent across different age groups, sexes, demographic factors, indications for PPI use, CCI scores, and other atopic diseases. However, further prospective studies are required to elucidate the causal mechanisms involved.

show abstract

Exposure to Proton Pump Inhibitors and the Risk of Incident Asthma in Patients with Coronary Artery Diseases: A Population-Based Cohort Study

Cited by 2 publications

References 27 publications

Individualized prevention of proton pump inhibitor related adverse events by risk stratification

Individualized prevention of proton pump inhibitor related adverse events by risk stratification

Proton-pump inhibitors are associated with an increased risk of asthma: A nationwide nested case-control study

Contact Info

Product

Resources

About